Swedbank AB Purchases 10,000 Shares of BioNTech SE Sponsored ADR $BNTX

Swedbank AB increased its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 25.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,900 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Swedbank AB’s holdings in BioNTech were worth $4,921,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. AG boosted its holdings in shares of BioNTech by 34.3% in the 1st quarter. B. Metzler seel. Sohn & Co. AG now owns 16,066 shares of the company’s stock valued at $1,463,000 after purchasing an additional 4,107 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of BioNTech by 94.6% during the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after buying an additional 581,173 shares during the last quarter. DAFNA Capital Management LLC boosted its stake in BioNTech by 23.5% in the first quarter. DAFNA Capital Management LLC now owns 10,500 shares of the company’s stock valued at $956,000 after buying an additional 2,000 shares in the last quarter. Nomura Holdings Inc. bought a new position in BioNTech in the first quarter valued at about $2,825,000. Finally, Royal Bank of Canada grew its position in BioNTech by 95.9% in the first quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after acquiring an additional 3,514 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BNTX. Jefferies Financial Group restated a “buy” rating and issued a $151.00 price target on shares of BioNTech in a research note on Wednesday, December 3rd. UBS Group upgraded shares of BioNTech to a “hold” rating in a research report on Thursday, December 4th. HC Wainwright reaffirmed a “buy” rating and set a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th. Morgan Stanley reiterated an “overweight” rating and issued a $134.00 price target on shares of BioNTech in a research note on Monday, November 3rd. Finally, Bank of America cut their price objective on BioNTech from $134.00 to $130.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Ten equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $137.75.

BioNTech Price Performance

Shares of NASDAQ:BNTX opened at $94.52 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.02 and a current ratio of 7.12. BioNTech SE Sponsored ADR has a 52 week low of $81.20 and a 52 week high of $129.27. The firm has a market cap of $21.28 billion, a PE ratio of -35.94 and a beta of 1.30. The firm’s fifty day moving average is $100.07 and its 200-day moving average is $104.11.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.75 by ($0.89). The company had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.21 billion. BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.81 earnings per share. Sell-side analysts predict that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

BioNTech Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.